Clinical Trial Update: Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating ribociclib in advanced neuroendocrine tumors of foregut origin has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neuroendocrine Neoplasm
• Duodenal Neuroendocrine Tumor
• Functional Pancreatic Neuroendocrine Tumor
• Gastric Neuroendocrine Tumor
• Lung Neuroendocrine Neoplasm
• Nonfunctional Pancreatic Neuroendocrine Tumor
• Thymus Neoplasm

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1 | Phase 2 | Status: COMPLETED | Results posted: 2020-10-30